drugset / Trial / NCT01993940

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

NCT01993940

Phase 3 Completed 553 enrolled Shionogi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in adults with non-malignant chronic pain who are not using laxatives.

Timeline

Start
2013-11-04
Primary completion
2015-06-09
Completion
2015-06-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Naldemedine Other / unclassified 0.2 mg Oral